Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment

MT Newswires Live

01/15

Acadia Pharmaceuticals (ACAD) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.

Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.

Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.

The company's shares were down 4.9% in recent trading.

Price: 17.03, Change: -0.87, Percent Change: -4.86

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503503979"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503503979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503503979?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 00:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503503979","market":"sg","top_or_hot":-1,"title":"Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment","media":"MT Newswires Live","content":"<html><body><p> Acadia Pharmaceuticals (ACAD) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.</p><p>Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.</p><p>Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.</p><p>The company's shares were down 4.9% in recent trading.</p><p>Price: 17.03, Change: -0.87, Percent Change: -4.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-15 00:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Acadia Pharmaceuticals (ACAD) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.</p><p>Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.</p><p>Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.</p><p>The company's shares were down 4.9% in recent trading.</p><p>Price: 17.03, Change: -0.87, Percent Change: -4.86</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503503979","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503503979","pubTimestamp":1736871966,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acadia Pharmaceuticals  said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.The company's shares were down 4.9% in recent trading.Price: 17.03, Change: -0.87, Percent Change: -4.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4231":"零售房地产信托","BK4156":"煤与消费用燃料","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4080":"零售业房地产投资信托","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","AKR":"阿卡迪亚房地产信托","ACAD":"阿卡迪亚"},"translate_title":"Acadia Pharmaceuticals寻求欧盟上市批准用于Rett综合征治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAD":0.9,"AKR":1},"content_text":"Acadia Pharmaceuticals (ACAD) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.The company's shares were down 4.9% in recent trading.Price: 17.03, Change: -0.87, Percent Change: -4.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}